Atieh Asgari
Overview
Explore the profile of Atieh Asgari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
13
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghanbari S, Gohari S, Reshadmanesh T, Mahjani M, Arsang-Jang S, Ismail-Beigi F, et al.
J Diabetes Metab Disord
. 2024 Jun;
23(1):1107-1111.
PMID: 38932825
Background: Sodium glucose co-transporter2 (SGLT2) inhibitors have exhibited cardioprotective properties in diabetes patients. The aim of this study was to investigate the effect of Empagliflozin on changes in echocardiographic parameters....
2.
Taheri H, Chiti H, Reshadmanesh T, Gohari S, Jalilvand A, Arsang-Jang S, et al.
J Diabetes Metab Disord
. 2023 Nov;
22(2):1723-1730.
PMID: 37975102
Background: Empagliflozin is a sodium glucose cotransporter-2 (SGLT2) inhibitor that has been suggested to improve cardiac function and vascular recovery. The risk of coronary artery diseases is much higher in...
3.
Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, et al.
Diabetol Metab Syndr
. 2022 Nov;
14(1):170.
PMID: 36397128
Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet...